Clinical applications of mifepristone
- 1 January 2006
- journal article
- review article
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 22 (12) , 655-659
Abstract
Mifepristone is a progesterone antagonist that has been studied for a number of clinical applications. It is a well-known abortifacient that is effective for both first- and second-trimester medical abortion when used with a prostaglandin analog. It is also an effective cervical priming agent that can be used to soften the cervix before surgical evacuation. Its clinical efficacy as an emergency contraception has been proven. Other applications including treatment for fibroids, endometriosis and various cancers have been explored. However, its association with abortion limits the applications of mifepristone in many of these areas.Keywords
This publication has 43 references indexed in Scilit:
- Mifepristone-induced cervical ripening: Structural, biomechanical, and molecular eventsAmerican Journal of Obstetrics and Gynecology, 2006
- Medical abortion at 57 to 63 days’ gestation with a lower dose of mifepristone and gemeprostActa Obstetricia et Gynecologica Scandinavica, 2001
- Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trialBJOG: An International Journal of Obstetrics & Gynaecology, 2000
- Comparison of vaginal misoprostol and gemeprost as pretreatment in first trimester pregnancy interruptionBJOG: An International Journal of Obstetrics & Gynaecology, 1999
- Oral misoprostol versus mifepristone for cervical dilatation before vacuum aspiration in first trimester nulliparous pregnancy: a double blind prospective randomised studyBJOG: An International Journal of Obstetrics & Gynaecology, 1996
- A comparison of 600 and 200 mg mifepristone prior to second trimester abortion with the prostaglandin misoprostolBJOG: An International Journal of Obstetrics & Gynaecology, 1996
- Induction of Abortion with Mifepristone (RU 486) and Oral or Vaginal MisoprostolNew England Journal of Medicine, 1995
- Cervical priming with prostaglandin E1 analogues, misoprostol and gemeprostThe Lancet, 1994
- Pretreatment with mifepristone (RU 486) reduces interval between prostaglandin administration and expulsion in second trimester abortionBJOG: An International Journal of Obstetrics & Gynaecology, 1990
- lntracervical TentsObstetrical & Gynecological Survey, 1989